Roche divarasib KRAS G12C investigational program achieved a historic milestone today as Roche announced positive top-line results from its pivotal Phase III Krascendo 1 study. This global trial evaluated divarasib, an oral, next-generation inhibitor, directly against approved first-generation treatments sotorasib and adagrasib. The trial met both its primary and key secondary endpoints in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring the specific KRAS G12C mutation.
According to data released, the trial demonstrated clinically meaningful and statistically significant improvements in both progression-free survival (PFS) and overall survival (OS). Crucially, statistical significance for overall survival was reached during the interim analysis of this historically poor-prognosis patient population. The safety profile remained consistent with historical data, showing no new safety signals, with the most common treatment-related adverse events being highly manageable and reversible.
The superior survival demonstrated in this global head-to-head comparison of KRAS G12C inhibitors confirms the potential of divarasib to improve clinical outcomes for people with KRAS G12C non-small cell lung cancer.
Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development
Krascendo 1 Trial Metrics and the Roche Divarasib KRAS G12C Mechanism
The Krascendo 1 study represents the only global head-to-head clinical trial directly comparing a next-generation KRAS targeting agent to approved first-generation alternatives. This randomized, open-label, multicenter phase III study evaluated 338 adults assigned to receive either daily oral divarasib, daily sotorasib, or twice-daily adagrasib. Blinded independent central review (BICR) served as the primary assessment method for progression-free survival, while secondary measures tracked overall survival, confirmed objective response, and duration of response.
In terms of molecular action, the KRAS gene normally regulates cellular growth by cycling between active (“on”) and inactive (“off”) states. However, the G12C mutation locks the protein in a continuous “on” state, driving unregulated tumor proliferation. Preclinical studies indicate that the Roche divarasib KRAS G12C compound features vastly improved potency and selectivity compared to first-generation treatments, successfully locking the mutant protein back into its inactive “off” state to halt tumor signaling.
Future Outlook and the Roche Divarasib KRAS G12C Clinical Programme
To maximize the clinical utility of this therapeutic breakthrough, a comprehensive phase III development strategy is currently underway. This includes evaluating the drug as a monotherapy, an early-stage adjuvant option, and a chemotherapy-free combination across various lines of therapy.
The detailed breakdown of the ongoing clinical program is structured below:
| Study Identifier | Therapeutic Intervention | Target Patient Population | Clinical Line of Therapy |
| Krascendo 1 (NCT06497556) | Divarasib monotherapy vs sotorasib or adagrasib | Previously treated KRAS G12C-mutant advanced or metastatic NSCLC | Second-line |
| Krascendo 2 (NCT06793215) | Divarasib plus pembrolizumab vs chemotherapy plus pembrolizumab | Previously untreated KRAS G12C-mutant advanced NSCLC | First-line (Chemotherapy-free) |
| Krascendo 3 (NCT07541170) | Adjuvant divarasib monotherapy vs immunotherapy or observation | Resected stage II–IIIB KRAS G12C-mutant NSCLC after standard chemoimmunotherapy | Early-stage (Post-resection) |
This expanding research ecosystem builds upon a deep foundation of therapeutic innovation. Patients and clinicians can review more updates via the internal Roche oncology portfolio
to track the continuous development of novel agents like Alecensa, Tecentriq, and Rozlytrek. Having received FDA Breakthrough Therapy Designation in 2022 and Orphan Drug Designation in 2026, the Roche divarasib KRAS G12C program continues to chart a swift path toward becoming an accessible clinical reality.
